Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MΔvjbR strain in goats.
Brucella
Brucellosis
Goats
Microencapsulation
Vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
15 01 2021
15 01 2021
Historique:
received:
08
06
2020
revised:
07
11
2020
accepted:
11
11
2020
pubmed:
18
12
2020
medline:
28
4
2021
entrez:
17
12
2020
Statut:
ppublish
Résumé
Small ruminant brucellosis is caused by the Gram negative cocci-bacillus Brucella (B.) melitensis, the most virulent Brucella species for humans. In goats and sheep, middle to late-term gestation abortion, stillbirths and the delivery of weak infected offspring are the characteristic clinical signs of the disease. Vaccination with the currently available Rev. 1 vaccine is the best option to prevent and control the disease, although it is far from ideal. In this study, we investigate the safety of the B. melitensis 16MΔvjbR strain during a 15-month period beginning at vaccination of young goats, impregnation, delivery and lactation. Forty, 4 to 6 months old, healthy female crossbreed goats were randomly divided into four groups (n = 10) and immunized subcutaneously with a single vaccine dose containing 1x10
Identifiants
pubmed: 33328142
pii: S0264-410X(20)31473-0
doi: 10.1016/j.vaccine.2020.11.033
pmc: PMC8730362
mid: NIHMS1654865
pii:
doi:
Substances chimiques
Brucella Vaccine
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-625Subventions
Organisme : FIC NIH HHS
ID : K01 TW009981
Pays : United States
Organisme : NIH HHS
ID : T32 OD011083
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Allison Rice-Ficht, managing partner of NanoRelease Technologies (NRT), LLC Inc., has a 95% equity interest in NRT, a company involved in vaccine delivery platforms. The terms of this arrangement have been reviewed and approved by Texas A&M Agri-Life Research and Texas A&M University in accordance with their conflict of interest policies].
Références
Ann Rech Vet. 1992;23(2):177-88
pubmed: 1610080
Clin Vaccine Immunol. 2012 Feb;19(2):249-60
pubmed: 22169089
PLoS Negl Trop Dis. 2017 Aug 17;11(8):e0005692
pubmed: 28817647
Infect Immun. 2009 Feb;77(2):877-84
pubmed: 19047401
Microb Pathog. 2018 Nov;124:250-257
pubmed: 30149131
Vet Rec. 1981 Jun 6;108(23):500
pubmed: 6795789
Infect Immun. 2008 Jun;76(6):2448-55
pubmed: 18362129
PLoS One. 2015 Sep 09;10(9):e0136696
pubmed: 26352261
J Infect Dis. 2011 Apr 15;203(8):1136-46
pubmed: 21451002
Immunol Rev. 2011 Mar;240(1):211-34
pubmed: 21349096
Prilozi. 2010;31(1):145-65
pubmed: 20703189
Trop Anim Health Prod. 1987 May;19(2):65-74
pubmed: 3307078
J Bacteriol. 1957 Feb;73(2):211-7
pubmed: 13416171
Vaccine X. 2019 Aug 22;3:100041
pubmed: 31528851
Immunology. 1977 Apr;32(4):373-81
pubmed: 608675
Pharm Dev Technol. 1996 Apr;1(1):63-8
pubmed: 9552332
Rev Sci Tech. 2013 Apr;32(1):43-51, 53-60
pubmed: 23837364
J Clin Microbiol. 1988 Jun;26(6):1120-3
pubmed: 3133389
Vet Res. 2019 Nov 27;50(1):100
pubmed: 31775863
BMC Microbiol. 2010 Jun 08;10:167
pubmed: 20529360
Ann Rech Vet. 1989;20(2):205-13
pubmed: 2751232
PLoS One. 2019 Mar 5;14(3):e0212457
pubmed: 30835758
PLoS Negl Trop Dis. 2019 Jan 18;13(1):e0007112
pubmed: 30657765